Search for: "Lisa Nicholson " Results 1 - 20 of 83
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 May 2024, 3:52 pm by Reference Staff
In the webinar The Importance of Language — How to Use Inclusive Communications to Advance Equity in the Administration of Justice, Lisa Burke of the New Jersey Administrative Office of the Courts, discusses how “white supremacy situates as the norm or as the reference point some generalized white experience. [read post]
23 Jan 2024, 11:32 am by Camilla Hrdy
   Other pre-ChatGPT work I found helpful: Carys Craig (copyright and AI authorship) Daryl Lim (AI and innovation policy), Arti Rai & Nicholson Price (medicine drug development machine learning). [read post]
29 Dec 2022, 9:05 pm by Victoria Hawekotte
In lieu of our regular Friday feature—the Week in Review—The Regulatory Review is recapping some of the top regulatory news from the past year, including major U.S. [read post]
3 Mar 2022, 6:43 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsSince the pandemic began, numerous recovered COVID-19 patients have reported having “long COVID”: COVID-19 symptoms persisting well beyond the underlying viral infection period. [read post]
21 Jan 2022, 8:35 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceThe FDA has now authorized three vaccines and several treatments (including both monoclonal antibodies and small-molecule drugs) for the prevention and treatment of COVID-19. [read post]
27 Sep 2021, 7:26 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsHistorically, the United States’ preparedness for a pandemic is like Charles Dudley Warner’s aphorism on the weather: everybody talks about it but no one ever does anything. [read post]
27 Aug 2021, 12:18 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn previous blog posts in this series, we have explored the roles different federal agencies, including the NIH, FDA, and CMS, play in the development and distribution of new healthcare technologies in the fight against COVID-19. [read post]
3 Jun 2021, 8:56 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsRecently, Pfizer and BioNTech and Moderna announced that they are seeking full FDA approval for their mRNA COVID-19 vaccines—filing, in FDA parlance, a Biologics License Application (BLA). [read post]
3 May 2021, 8:36 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceWe have written before about the challenges of making decisions under scientific uncertainty and the simultaneous importance and difficulty of developing high-quality clinical evidence under pandemic circumstances. [read post]